文献速递甲状腺疾病

基于血浆循环肿瘤DNA二代测序的甲状腺癌基因组图谱特征分析

Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
PubMed 文献 · Thyroid · 2023-12-22

该回顾性数据分析纳入2016至2021年Guardant360血浆NGS检测的1094例成人甲状腺癌患者,其中876例为甲状腺癌未分型。78.3%的患者检出至少一个基因组改变,TP53突变最常见(46.9%)。ATC的平均血液肿瘤突变负荷高于其他类型甲状腺癌。

要点

  • 78.3%的甲状腺癌患者通过血浆ctDNA NGS检出至少一个基因组改变。
  • TP53突变在所有甲状腺癌中最常见,检出率为46.9%。
  • RET、ALK和NTRK融合在所有甲状腺癌中检出率分别为1.1%、0.5%和0.2%。

核心结论

  • 血浆全面NGS是甲状腺癌中有前景的NGS方法,但尚需通过配对肿瘤和血浆样本分析来验证其临床实用性。

研究设计与样本

  • 回顾性数据分析,使用商业化Guardant360血浆NGS检测对2016至2021年收集的1094例成人甲状腺癌患者样本进行分析,中位年龄65岁(范围10-98),47.3%为男性。

主要发现

  • 1094例患者中876例为甲状腺癌未分型,20%有具体诊断(92例ATC、62例PTC、14例FTC、16例OCA、2例PDTC、32例MTC)。
  • 78.3%的患者通过ctDNA NGS检出至少一个基因组改变,TP53突变在所有甲状腺癌中最常见(46.9%)。
  • BRAFV600E在27.2%的ATC、35.7%的PTC中检出,FTC中未检出。
  • RAS在18.5%的ATC、11.9%的PTC、62.5%的FTC中检出;RET、ALK和NTRK融合在所有甲状腺癌中检出率分别为1.1%、0.5%和0.2%;RET突变在66.7%的MTC中检出。
  • 159例患者进行了bTMB分析,ATC的平均bTMB高于其他类型甲状腺癌(p=0.0011、0.0557和<0.0001)。

局限性

  • 原文结论指出,尚需通过配对肿瘤和血浆样本分析来验证血浆NGS在甲状腺癌中的临床实用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The limited availability of targeted therapies in thyroid cancer (TC) has challenged conventional treatment algorithms and has established urgency for the identification of targetable genomic abnormalities. In addition to widely adopted tissue-based next-generation sequencing (NGS), plasma-based circulating tumor DNA (ctDNA) NGS is rapidly emerging as a genomic biomarker detection method and is steadily gaining utility across solid tumors. To date, plasma-based genomic alterations in TC have not been determined. Herein, we profile potential actionable mutations detected through ctDNA in patients with TC subtypes. Methods: A retrospective data analysis of the Guardant Health, Inc. database was performed using the commercially available Guardant360® plasma-NGS test on TC samples from adult patients collected between 2016 and 2021. The landscape of genomic alterations and blood tumor mutation burden (bTMB) were analyzed in patients with different types of TC: anaplastic TC (ATC), papillary TC (PTC), follicular TC (FTC), oncolytic carcinoma of the thyroid (OCA), poorly differentiated TC (PDTC), medullary TC (MTC), and TC not otherwise specified (TC NOS). Results: Of the 1094 patients included most of the patients n = 876 had TC NOS, and 20% had a specific diagnosis (92 ATC, 62 PTC, 14 FTC, 16 OCA, 2 PDTC, and 32 MTC patients). The median age was 65 (range 10-98) and 47.3% were male. 78.3% of patients had one or more genomic alteration detected by ctDNA NGS. TP53 (46.9%) was the most common mutation detected among all TC. BRAFV600E was detected in 27.2% of ATC, 35.7% of PTC, and in none of FTC. RAS was detected in 18.5% of ATC, 11.9% of PTC, and 62.5% of FTC. RET, ALK, and NTRK fusions were seen in 1.1%, 0.5%, and 0.2% of all TC, respectively. RET mutations were detected in 66.7% of MTC. bTMB analysis was performed on 159 patients. The mean bTMB was higher in ATC compared with other types of TC (p = 0.0011, 0.0557, and <0.0001, respectively). Conclusions: Plasma-based comprehensive NGS is a promising NGS method in TC; however, future validation of the clinical utility by analysis of paired tumor and plasma samples is needed.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Tarasova VD, Tsai J, Masannat J, et al. Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing. Thyroid. 2023. PMID: 37962267. doi:10.1089/thy.2023.0204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。